Literature DB >> 15781660

Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype.

Johannes V Swinnen1, Annelies Beckers, Koen Brusselmans, Sophie Organe, Joanna Segers, Leen Timmermans, Frank Vanderhoydonc, Ludo Deboel, Rita Derua, Etienne Waelkens, Ellen De Schrijver, Tine Van de Sande, Agnès Noël, Fabienne Foufelle, Guido Verhoeven.   

Abstract

Aggressive cancer cells typically show a high rate of energy-consuming anabolic processes driving the synthesis of lipids, proteins, and DNA. Here, we took advantage of the ability of the cell-permeable nucleoside 5-aminoimidazole-4-carboxamide (AICA) riboside to increase the intracellular levels of AICA ribotide, an AMP analogue, mimicking a low energy status of the cell. Treatment of cancer cells with AICA riboside impeded lipogenesis, decreased protein translation, and blocked DNA synthesis. Cells treated with AICA riboside stopped proliferating and lost their invasive properties and their ability to form colonies. When administered in vivo, AICA riboside attenuated the growth of MDA-MB-231 tumors in nude mice. These findings point toward a central tie between energy, anabolism, and cancer and suggest that the cellular energy sensing machinery in cancer cells is an exploitable target for cancer prevention and/or therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781660     DOI: 10.1158/0008-5472.CAN-04-3025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.

Authors:  Biplab Dasgupta; Rishi Raj Chhipa
Journal:  Trends Pharmacol Sci       Date:  2015-12-20       Impact factor: 14.819

2.  AMP-activated protein kinase promotes human prostate cancer cell growth and survival.

Authors:  Hyeon Ung Park; Simeng Suy; Malika Danner; Vernon Dailey; Ying Zhang; Henghong Li; Daniel R Hyduke; Brian T Collins; Gregory Gagnon; Bhaskar Kallakury; Deepak Kumar; Milton L Brown; Albert Fornace; Anatoly Dritschilo; Sean P Collins
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

3.  FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma.

Authors:  Olga V Danilova; Larry J Dumont; Norman B Levy; Frederick Lansigan; William B Kinlaw; Alexey V Danilov; Prabhjot Kaur
Journal:  J Hematop       Date:  2013-03       Impact factor: 0.196

4.  AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia.

Authors:  Jeffim N Kuznetsov; Guy J Leclerc; Gilles M Leclerc; Julio C Barredo
Journal:  Mol Cancer Ther       Date:  2011-01-24       Impact factor: 6.261

5.  AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival.

Authors:  Jennifer Woodard; Leonidas C Platanias
Journal:  Biochem Biophys Res Commun       Date:  2010-06-17       Impact factor: 3.575

Review 6.  Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing.

Authors:  Petras Dzeja; Andre Terzic
Journal:  Int J Mol Sci       Date:  2009-04-17       Impact factor: 6.208

7.  Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA.

Authors:  Julia Ling-Yu Chen; Daniel Merl; Christopher W Peterson; Jianli Wu; Patrick Yantyng Liu; Hanwei Yin; Deborah M Muoio; Don E Ayer; Mike West; Jen-Tsan Chi
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

8.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

9.  The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.

Authors:  Deliang Guo; Isabel J Hildebrandt; Robert M Prins; Horacio Soto; Mary M Mazzotta; Julie Dang; Johannes Czernin; John Y-J Shyy; Andrew D Watson; Michael Phelps; Caius G Radu; Timothy F Cloughesy; Paul S Mischel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-22       Impact factor: 11.205

10.  Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.

Authors:  Guillaume Robert; Issam Ben Sahra; Alexandre Puissant; Pascal Colosetti; Nathalie Belhacene; Pierre Gounon; Paul Hofman; Fréderic Bost; Jill-Patrice Cassuto; Patrick Auberger
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.